Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21820442 | 1.00 | HPGD (0.47) | HPGDMAPTKDM4EOPRK1CYP1A2 | |
| SCHEMBL21808113 | 1.00 | HPGD (0.47) | HPGDMAPTKDM4EOPRK1CYP1A2 | |
| SCHEMBL29833061 | 1.00 | HPGD (0.47) | HPGDMAPTKDM4EOPRK1CYP1A2 | |
| SCHEMBL28904938 | 0.88 | ALDH1A1 (0.55) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL28904936 | 0.88 | ALDH1A1 (0.55) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL21820526 | 0.82 | NPC1 (0.44) | HPGDMAPTKDM4EOPRK1CYP1A2 | |
| SCHEMBL21820416 | 0.82 | NPC1 (0.44) | HPGDMAPTKDM4EOPRK1CYP1A2 | |
| SCHEMBL21820575 | 0.77 | ALDH1A1 (0.51) | HPGDMAPTKDM4EOPRK1CYP1A2 | |
| SCHEMBL21820572 | 0.77 | ALDH1A1 (0.51) | HPGDMAPTKDM4EOPRK1CYP1A2 | |
| SCHEMBL29832662 | 0.77 | ALDH1A1 (0.51) | HPGDMAPTKDM4EOPRK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | TERNS PHARMACEUTICALS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250276961-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. | 2025-09-04 | — | — | US | disclosed |
| US-20250243184-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. | 2025-07-31 | — | — | US | disclosed |
| US-12240835-B2 | Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity | TERNS PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20240101536-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | TERNS PHARMACEUTICALS, INC. | 2024-03-28 | — | — | US | disclosed |
| CN-115448908-A | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-115215838-A | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-112770745-B | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-112770745-A | Compounds for the treatment of specific leukemias | 拓臻股份有限公司 | 2021-05-07 | — | — | CN | disclosed |
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | Terns, Inc. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | Terns, Inc. (US) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240835-B2 | Substituted benzamides as intermediates in the synthesis of inhibitors of tyrosine kinase enzymatic activity | ABL1, BCR, ABL2 | HPGD 4229/4885MAPT 4351/4885KDM4E 1611/4885 |
| US-20200087283-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | HPGD 3856/4885MAPT 3993/4885KDM4E 1680/4885 |
| US-20250276961-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | HPGD 3856/4885MAPT 3993/4885KDM4E 1680/4885 |
| US-20250243184-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | HPGD 3856/4885MAPT 3993/4885KDM4E 1680/4885 |
| US-10889571-B2 | Substituted benzoimidazoles and imidazo[4,5-c]pyridines for treating certain leukemias | ABL1, ABL2, BCR | HPGD 3518/4885MAPT 4090/4885KDM4E 720/4885 |
| US-12454524-B2 | (r)-n-(4-(chlorodifluoromethoxy)phenyl)-2-(difluoromethyl)-1-(1-hydroxypropan-2-yl)-7-(pyrimidin-5-yl)-1H-benzo[d]imidazole-5-carboxamide, or a pharmaceutically acceptable salt or tautomer thereof, for treating certain leukemias | ABL1, ABL2, BCR | HPGD 3906/4885MAPT 263/4885KDM4E 1247/4885 |
| US-20240101536-A1 | COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS | ABL1, ABL2, BCR | HPGD 3856/4885MAPT 3993/4885KDM4E 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.